Relationship between long-term use of a typical antipsychotic medication by Chinese schizophrenia patients and the bone turnover markers serum osteocalcin and β-CrossLaps

Schizophrenia Research

Volumn 176, Issue 2-3, 2016, Pages 259-263

  Zhang, Beibei ^a   Deng, Lu ^a   Wu, Haishan ^a   Lu, Xiaozi ^b   Peng, Lihong ^a   Wu, Renrong ^a   Guo, Wenbin ^a   Chen, Jindong ^a   Li, Lehua ^a   Zhao, Jingping ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b SHANDONG MENTAL HEALTH CENTER   (China)

Author keywords

Antipsychotics; Bone turnover; Glucose; Lipid; Osteoporosis; Schizophrenia

Indexed keywords

CARBOXY TERMINAL TELOPEPTIDE; ESTRADIOL; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LIPID; NEUROLEPTIC AGENT; OLANZAPINE; OSTEOCALCIN; PARATHYROID HORMONE; PROLACTIN; RISPERIDONE; SEX HORMONE; TESTOSTERONE; TRIACYLGLYCEROL; BIOLOGICAL MARKER; COLLAGEN; GLUTAMYL-LYSYL-ALANYL-HISTIDYL-ASPARTYL-GLYCYL-GLYCYL-ARGININE; PEPTIDE FRAGMENT;

ADULT; AGE DISTRIBUTION; ARTICLE; BODY MASS; BONE METABOLISM; BONE TURNOVER; CHINESE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISORDERS OF CARBOHYDRATE METABOLISM; DYSLIPIDEMIA; FEMALE; GLUCOSE BLOOD LEVEL; HORMONE BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LIPID BLOOD LEVEL; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; OSTEOLYSIS; PARATHYROID HORMONE BLOOD LEVEL; PHYSICAL EXAMINATION; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; SCHIZOPHRENIA; SEX DIFFERENCE; TREATMENT DURATION; ADOLESCENT; BLOOD; BONE REMODELING; DRUG EFFECTS; PSYCHOLOGICAL RATING SCALE; STATISTICAL MODEL; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; BIOMARKERS; BONE REMODELING; COLLAGEN; FEMALE; HUMANS; LINEAR MODELS; MALE; OSTEOCALCIN; PEPTIDE FRAGMENTS; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; YOUNG ADULT;

EID: 84995603555     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2016.06.034     Document Type: Article

References (25)

1. Abraham, G., Paing, W.W., Kaminski, J., Joseph, A., Kohegy, E., Josiassen, R.C., Effects of elevated serum prolactin on bone mineral density and bone metabolism in female patients with schizophrenia: a prospective study. Am. J. Psychiatry 160:9 (2003), 1618–1620.
2. Bishop, J.R., Rubin, L.H., Reilly, J.L., Pavuluri, M.N., Sweeney, J.A., Risperidone-associated prolactin elevation and markers of bone turnover during acute treatment. Ther. Adv. Psychopharmacol. 2 (2012), 95–102.
3. Bruce, J.K., Hong, L.S., Virginia, L.S., Jayanthi, J., Bone loss associated with hyperprolactinemia in patients with schizophrenia. Clin. Schizophr. Relat. Psychoses 7:3 (2013), 115–123.
4. Chailurkit, L., Chanprasertyothin, S., Rajatanavin, R., Ongphiphadhanakul, B., Reduced attenuation of bone resorption after oral glucose in type 2 diabetes. Clin. Endocrinol. 68:6 (2008), 858–862.
5. Doknic, M., Maric, N.P., Britvic, D., et al. Bone remodeling, bone mass and weight gain in patients with stabilized schizophrenia in real-life conditions treated with long-acting injectable risperidone. Neuroendocrinology 94:3 (2011), 246–254.
6. Fujimaki, T., Kurabayashi, T., Ootani, T., Yamamoto, Y., Yasuda, M., Tanaka, K., A study on bone metabolism in woman with hyperprolactinemia. Acta Obstet. Gynaecol. Jpn. 46:5 (1994), 423–428.
7. Garnero, P., Sornay-Rendu, E., Claustrat, B., Delmas, P.D., Biochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women: the OFELY study. J. Bone Miner. Res. 15:8 (2000), 1526–1536.
8. Guo, X., Zhang, Z., Zhai, J., Wu, R., Liu, F., Zhao, J., The relationship between obesity and health-related quality of life in Chinese patients with schizophrenia. Int. J. Psychiatry Clin. Pract. 17:1 (2013), 16–20.
9. Halbreich, U., Kinon, B.J., Gilmore, J.A., Kahn, L.S., Elevated prolactin levels in patients with schizophrenia: mechanisms and related adverse effects. Psychoneuroendocrinology 28:Suppl. 1 (2003), 53–67 (15).
10. Henriksen, D.B., Alexandersen, P., Bjarnason, N.H., et al. Role of gastrointestinal hormones in postprandial reduction of bone resorption. J. Bone Miner. Res. 18:12 (2003), 2180–2189.
11. Jeong, T.D., Lee, W., Choi, S.E., Kim, J.S., et al. Relationship between serum total cholesterol level and serum biochemical bone turnover markers in healthy pre- and postmenopausal women. Biomed. Res. Int., 2014(1), 2014, 398397.
12. Kishimoto, T., Watanabe, K.N., Makita, K., Yagi, G., Kashima, H., Antipsychotic-induced hyperprolactinemia inhibits the hypothalamo-pituitary-gonadal axis and reduces bone mineral density in male patients with schizophrenia. J. Clin. Psychiatry 69:3 (2008), 385–391.
13. Kunchur, R., Need, A., Hughes, T., Goss, A., Clinical investigation of C-terminal cross-linking telopeptide test in prevention and management of bisphosphonate-associated osteonecrosis of the jaws. J. Oral. Maxillofac. Surg. 67 (2009), 1167–1173.
14. Laet, C.D., Kanis, J.A., Odén, A., et al. Body mass index as a predictor of fracture risk: a meta-analysis. Osteoporos. Int. 16:11 (2005), 1330–1338.
15. Majima, T., Shimatsu, A., Komatsu, Y., et al. Increased bone turnover in patients with hypercholesterolemia. Endocr. J. 55:1 (2008), 143–151.
16. Meyer, J.M., Koro, C.E., The effects of antipsychotic therapy on serum lipids: a comprehensive review. Schizophr. Res. 70:1 (2004), 1–17.
17. O'Keane, V., Antipsychotic-induced hyperprolactinaemia, hypogonadism and osteoporosis in the treatment of schizophrenia. J. Psychopharmacol. 22:2 Suppl (2008), 70–75.
18. Okamoto, K., Inaba, M., Furumitsu, Y., et al. Beneficial effect of risedronate on arterial thickening and stiffening with a reciprocal relationship to its effect on bone mass in female osteoporosis patients: a longitudinal study. Life Sci. 87 (2010), 686–691.
19. Pramojanee, S.N., Phimphilai, M., Chattipakorn, N., Chattipakorn, S.C., Possible roles of insulin signaling in osteoblasts. Endocr. Res. 39:4 (2014), 144–151.
20. Starup-Linde, J., Eriksen, S.A., Lykkeboe, S., Handberg, A., Vestergaard, P., Biochemical markers of bone turnover in diabetes patients—a meta-analysis, and a methodological study on the effects of glucose on bone markers. Osteoporos. Int. 25:6 (2014), 1697–1708.
21. Thomas, P., Barbara, S., Johannes, M., Meinrad, P., Stefan, K., Influence of age and gender on associations of body mass index with bone mineral density, bone turnover markers and circulating calcium-regulating and bone-active sex hormones. Bone 49:4 (2011), 824–829.
22. Thrailkill, K.M., Lumpkin C.K. Jr., Bunn, R.C., Kemp, S.F., Fowlkes, J.L., Is insulin an anabolic agent in bone? dissecting the diabetic bone for clues. Am. J. Physiol. Endocrinol. Metab. 289:5 (2005), E735–E745.
23. Wu, X., Huang, Z., Wu, R., et al. The comparison of glycometabolism parameters and lipid profiles between drug-naive, first-episode schizophrenia patients and healthy controls. Schizophr. Res. 150 (2013), 157–162.
24. Young, S.L., Taylor, M., Lawrie, S.M., “First do no harm.” a systematic review of the prevalence and management of antipsychotic adverse effects. J. Psychopharmacol. 29:4 (2014), 353–362.
25. Zhou, M., Ma, X., Li, H., et al. Serum osteocalcin concentrations in relation to glucose and lipid metabolism in chinese individuals. Eur. J. Endocrinol. 161:5 (2009), 723–729.